Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 5/20 | 0.66 |
| ▸ | BACE1 | P56817 | 5/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30734208 | 0.96 | HTT (0.61) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL18177905 | 0.88 | HTT (0.70) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL30734225 | 0.84 | HTT (0.67) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL13621630 | 0.80 | HTT (1.00) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL30734134 | 0.80 | ACHE (0.58) | HTTALDH1A1ACHEBACE1AURKA | |
| SCHEMBL30734186 | 0.79 | ACHE (0.60) | HTTALDH1A1ACHEBACE1AURKA | |
| SCHEMBL27644467 | 0.77 | HTT (0.75) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL30734191 | 0.77 | ACHE (0.55) | HTTALDH1A1ACHEBACE1AURKA | |
| SCHEMBL22715242 | 0.77 | HTT (0.76) | HTTALDH1A1NPSR1ACHEBACE1 | |
| SCHEMBL29472072 | 0.77 | HTT (0.76) | HTTALDH1A1NPSR1ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543888-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250083-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | HTT 713/4885ALDH1A1 4568/4885NPSR1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.